What Are FDA Clinical Trial Labeling Requirements?

FDA clinical trial labeling requirements come from two sources that sit at very different heights. The binding federal regulation, 21 CFR 312.6, is short: it mandates a specific cautionary statement on the immediate container and prohibits any false or misleading claim about the drug. Everything else you see on a clinical trial label, including the sponsor name, lot number, protocol code, storage instructions, and expiration date, comes from ICH E6(R2) Good Clinical Practice, which the FDA has adopted as its expectation and enforces during inspections. Knowing which line is statutory and which is guidance matters when you are designing a label, defending one, or reading a Warning Letter.

The Mandatory Cautionary Statement

Every immediate package of an investigational drug intended for human use must carry a label reading: “Caution: New Drug—Limited by Federal (or United States) law to investigational use.”¹ The wording is fixed by 21 CFR 312.6(a). It appears on the container that directly holds the drug, not just the outer carton, so that anyone handling a loose vial or blister card can see it.

The statement is what separates an investigational product from an approved medication in a pharmacy or shipping room. It signals that the drug has not been cleared for commercial sale and can only be used inside an authorized investigation. The one exception in the regulation covers products designated for the Strategic National Stockpile, where an FDA Center Director may grant an alternative under specified procedures.¹

No False or Misleading Claims

The second binding rule under 21 CFR 312.6 prohibits any false or misleading statement on the label or in the labeling, and it prohibits any representation that the drug is safe or effective for the purposes being investigated.¹ The point of the trial is to answer that question, so labeling cannot answer it in advance.

“Labeling” reaches further than the sticker on the vial. In FDA usage it includes any written, printed, or graphic material that accompanies the drug: package inserts, instruction sheets, and material given to investigators. Sponsors preparing these documents have to make sure nothing in them implies proven benefit before the data supports that conclusion.

What GCP Expects on the Label

ICH E6(R2) Section 5.13 puts the sponsor in charge of ensuring investigational products are properly labeled and coded.² The elements that sponsors typically include on a clinical trial label are:

Sponsor or CRO name and contact information.
Product name, code, or unique identifier.
Dosage form and strength.
Lot or batch number for traceability to a specific production run.
Protocol number identifying the study under which the drug is authorized.
Storage conditions, including temperature range and any light or humidity requirements.
Expiration date or retest date.

The lot number has independent regulatory backing. 21 CFR 211.130 requires drug products to bear a lot or control number that permits determination of manufacturing and control history.³ For products manufactured under GMP conditions, an inspector can cite this section directly for a missing lot number.

Storage conditions get their own attention in ICH GCP 5.13.2, which places the obligation on the sponsor to determine acceptable temperatures, light protection, storage durations, and any reconstitution procedures, then to communicate those determinations to monitors, investigators, pharmacists, and storage staff.² If the expiration or retest date is extended based on new stability data, the sponsor is responsible for relabeling the product before it reaches the next patient. A label that no longer matches the data is the kind of mismatch 21 CFR 312.6(b) treats as misleading.

Immediate Container Versus Outer Packaging

A small vial or blister pack cannot fit every element in readable type. The standard solution is to load the full information onto the outer carton or shipping box and put an abbreviated version on the immediate container.

Whatever else is abbreviated, the immediate container must always carry the federal cautionary statement.¹ Beyond that, sponsors typically include the drug name or code, strength, and lot number on the immediate container, and keep the detailed storage instructions and full sponsor contact on the outer packaging or accompanying documentation.

The risk with this split is separation. If a vial is pulled from its carton and only the carton showed the expiration date, the person administering the drug has no way to check it. Careful label design puts the expiration date on both the immediate container and the outer packaging whenever space allows.

Labels for Blinded Trials

Blinding is where labeling collides with study design. The active drug, placebo, and any comparator must look identical, so neither the investigator nor the patient can tell them apart. ICH GCP 5.13.1 requires sponsors to code and label products in a way that protects the blinding.² In practice, the drug’s identity is replaced with a neutral term such as “Study Medication” and a randomization or kit number that ties the product to the patient and treatment arm through a secure database.

Variable information the site still needs stays legible: patient identification number, dosing instructions, and any sequence-specific data. The lot number and expiration date also remain, since neither reveals treatment assignment.

Emergency Unblinding

ICH GCP 5.13.4 requires the coding system to allow rapid identification in a medical emergency without permitting undetectable breaks of the blind. Sponsors typically satisfy this with sealed code-break envelopes or a 24-hour interactive response system that reveals the assignment when a patient’s safety requires it. If the blind is broken for any reason, the investigator must promptly document what happened and explain it to the sponsor, since regulators will look at unblinding events when they assess data integrity.⁴

How Labels Support Drug Accountability

Labels feed the accountability system that 21 CFR 312.62 requires investigators to maintain. Investigators must keep adequate records of drug disposition, including dates, quantities, and use by individual subjects.⁵ The lot number, kit number, and patient identification printed on the label are the data points that make those records traceable.

When a study is terminated, suspended, or completed, the investigator must return unused supplies to the sponsor or dispose of them under 21 CFR 312.59.⁵ Label information is what allows reconciliation of what was shipped, dispensed, and returned. A missing or illegible label is a gap in that chain, and auditors flag it.

Language of the Label

Federal regulation requires informed consent information to be presented “in language understandable to the subject” under 45 CFR 46.116.⁶ That rule governs consent documents and study materials. 21 CFR 312.6 itself does not specify what language the product label must use, but because the label cannot be misleading “in any particular,” a label a patient cannot read can raise concerns under that standard.

Multinational Trials

Sponsors running trials across multiple countries face overlapping rules. ICH GCP provides a common baseline, but details diverge. EU regulations require a “For clinical trial use only” statement comparable to the U.S. cautionary statement, along with the trial reference code, sponsor name and address, batch number, expiration date, and a unique patient identification code. The EU also requires the expiration date on the label itself; the FDA permits sponsors to keep expiration information in accompanying documentation when space on the immediate container is limited.

The practical approach for multi-country labels is to design against the most stringent requirement and then verify country-specific deviations. A label built for EU Annex 13 will usually satisfy 21 CFR 312.6 and ICH GCP, but the U.S. cautionary statement must still appear in its exact federally mandated wording.

What Happens When Labeling Falls Short

Labeling problems have real consequences under two enforcement tools.

Clinical Holds

The FDA may place a proposed or ongoing investigation on hold if it finds the investigator brochure misleading, erroneous, or materially incomplete.⁷ The provision applies to Phase 1 and is incorporated for Phase 2 and Phase 3. A hold stops enrollment and can halt dosing of enrolled subjects. The brochure and the product label are related documents, and labeling that contradicts the brochure, omits safety-relevant information, or makes claims the brochure does not support invites exactly this kind of scrutiny.

Warning Letters

When the FDA identifies significant violations during an inspection or review, it often issues a Warning Letter. These letters address concerns including poor manufacturing practices, problematic claims about what a product can do, and incorrect directions for use. The recipient responds with corrective actions, which the FDA verifies through follow-up inspection. If corrections are inadequate or violations continue, enforcement action may escalate without further notice.⁸

1
eCFR. 21 CFR 312.6 – Labeling of an Investigational New Drug
2
ICH. ICH E6(R2) Guideline for Good Clinical Practice
3
eCFR. 21 CFR 211.130 – Packaging and Labeling Operations
4
ICH. ICH E6(R2) Guideline for Good Clinical Practice – Step 5
5
eCFR. 21 CFR 312.62 – Investigator Recordkeeping and Record Retention
6
HHS.gov. Informed Consent of Subjects Who Do Not Speak English
7
eCFR. 21 CFR 312.42 – Clinical Holds and Requests for Modification
8
U.S. Food and Drug Administration. About Warning and Close-Out Letters